BioCatalyst

OR502, Cemiplimab — catalyst calendar

1 verified catalyst event(s) referencing OR502, Cemiplimab, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-01
in 1mo
ESTIMATED
 READOUT
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combinati
Phase 1/2 · Cancer, Tumor, Solid
 OncoResponse, Inc. OR502, Cemiplimab ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.